Paper32077604
Optimal management of chronic hepatitis B patients receiving nucleos(t)ide analogues.
Buti M and 3 others. Liver Int, 2020. Cited by 17 papers, by iCite.
Cite this record
ConductScience Library. Optimal management of chronic hepatitis B patients receiving nucleos(t)ide analogues. Papers, record 32077604. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32077604
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma, Hepatocellular | Major topic |
| Hepatitis B, Chronic | Major topic |
| Liver Neoplasms | Major topic |
| Antiviral Agents | |
| Humans | |
| Treatment Outcome |
Source PubMed
Cited by13
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 17 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42325368 | HBsAg loss in HIV/HBV coinfected patients: Hepatitis B cure insights and implications. | Infect Dis Immun | 2025 | https://conductscience.org/library/papers/42325368 | PubMed |
| 41810101 | Eight-year Results from Two Randomized Phase 3 Trials of Tenofovir Alafenamide for Chronic Hepatitis B Virus Infection in China. | J Clin Transl Hepatol | 2026 | https://conductscience.org/library/papers/41810101 | PubMed |
| 40890755 | Global trends and insights in interferon therapy for chronic hepatitis B: a bibliometric analysis. | Virol J | 2025 | https://conductscience.org/library/papers/40890755 | PubMed |
| 40667578 | Duration of Nucleos(t)ide Analogue Treatments in Patients With Chronic Hepatitis B Virus Infection in the United States. | J Viral Hepat | 2025 | https://conductscience.org/library/papers/40667578 | PubMed |
| 40653613 | Clinical Features of HBV-Related HCC in Long-Term NAs-Treated Versus Untreated Patients. | J Cell Mol Med | 2025 | https://conductscience.org/library/papers/40653613 | PubMed |
| 39101697 | Etiologies of Persistent Aminotransferase Elevations in Chronic Hepatitis B Patients Treated with Nucleos(t)ide Analogs. | Turk J Gastroenterol | 2024 | https://conductscience.org/library/papers/39101697 | PubMed |
| 38689751 | Prospective study of hepatitis B and D epidemiology and risk factors in Romania: A 10-year update. | World J Hepatol | 2024 | https://conductscience.org/library/papers/38689751 | PubMed |
| 35836769 | Impact of National Centralized Drug Procurement Policy on Antiviral Utilization and Expenditure for Hepatitis B in China. | J Clin Transl Hepatol | 2022 | https://conductscience.org/library/papers/35836769 | PubMed |
| 34630679 | Efficacy and safety of tenofovir alafenamide fumarate in nucleoside analogue treatment-naïve patients with chronic hepatitis B. | Exp Ther Med | 2021 | https://conductscience.org/library/papers/34630679 | PubMed |
| 33905426 | Demographics and outcomes of hepatitis B and D: A 10-year retrospective analysis in a Swiss tertiary referral center. | PLoS One | 2021 | https://conductscience.org/library/papers/33905426 | PubMed |
| 33614029 | Long-term efficacy and safety of nucleos(t)ides analogues in patients with chronic hepatitis B. | Ther Adv Infect Dis | 2021 | https://conductscience.org/library/papers/33614029 | PubMed |
| 32596332 | The Risk of Acute Kidney Injury in Hepatitis B Virus-Related Acute on Chronic Liver Failure with Tenofovir Treatment. | Biomed Res Int | 2020 | https://conductscience.org/library/papers/32596332 | PubMed |
| 32384507 | Comparative efficacy of the front-line anti-HBV drugs in nucleos(t)ide analogue-naive chronic hepatitis B: A protocol for systematic review and network meta-analysis. | Medicine (Baltimore) | 2020 | https://conductscience.org/library/papers/32384507 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/32077604
GET https://conductscience.org/api/papers/v1/32077604/authors